Authors: Anna Biggins, MPH, RDN, LD and Jaime Burkle, MD
Affiliation: Georgia Heart Institute
Background: Cardiovascular disease (CVD) remains the number one cause of death among Americans despite continual advances in treatment options. A healthy lifestyle throughout life is recognized as the most important prevention strategy against atherosclerotic cardiovascular disease (ASCVD). A team-based approach is acknowledged as an effective strategy for ASCVD prevention and improved patient outcomes. The Georgia Heart Institute launched the Prevention Center in 2022. The multidisciplinary care team comprises cardiologists, a nurse facilitator, dietitian, wellness coach, and medical assistants, resulting in a comprehensive clinical and lifestyle assessment of cardiovascular risk.
Purpose: This exploratory study examined population characteristics of prevention patients over 12 months for three main purposes: 1) Identify trends in clinical and demographic characteristics; 2) Identify gaps in equity of care; 3) Reveal opportunities to improve ASCVD risk reduction.
Methods: The electronic health record was audited to identify patients between August 2022 and August 2023 who underwent an assessment at the Prevention Center. A descriptive analysis of clinical and demographic variables was conducted.
Results: The Prevention Center encountered 870 new patients over 12 months. Fifty-two percent were female, 88% were white, 6.5% were Black, and 93% were non-Hispanic. The average age was 62 years, with 85% of patients being age 50 years or older. Key clinical characteristics included dyslipidemia (LDL >100mg/dL: 58%; TG >150mg/dL: 44%), poor glycemic control (A1c 5.7-6.4: 28%; A1c >6.5: 31%), and elevated ASCVD risk scores (35% with score 7.5%–20%; 18% with score >20%). Obesity and overweight were present in 53% and 32% of patients, respectively. Forty one percent of patients had hypertension. Family histories were significant for heart disease (57%), hypertension (54%), heart attack or stroke (49%), and diabetes (34%). The majority of patients had never smoked (59%). Out of the 116 patients with lipoprotein(a) results, 41% had Lp(a) levels >75 nmol/L.
Conclusion: This population analysis confirms the appropriateness of a multidisciplinary team to treat ASCVD and cardiometabolic risk factors. Patients displayed multiple comorbidities and a strong family history of heart disease, with lipoprotein(a) providing a targeted risk assessment. Gaps exist in racial and ethnic diversity considering the disproportionate burden of ASCVD present in Black individuals and those with South Asian ancestry. Only 15% of the patient population is below age 50 years, conflicting with the knowledge of ASCVD as a progressive disease with risk factors emerging as early as childhood. There exists a potential opportunity to strengthen partnerships with primary care providers to enhance ASCVD prevention across the lifespan.